**Piper sarmentosum** attenuates dexamethasone-induced hypertension by stimulating endothelial nitric oxide synthase

Azizah UGUSMAN 1*, Noor Fazilah MD FADZE 1, Adila A HAMID 1, Zanariyah ASMAWI 1, Amilia AMINUDDIN 1

1 Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

* Corresponding Author. E-mail: dr.azizah@ppukm.ukm.edu.my (A.U.); Tel. +603-9145 86 14.

Received: 12 September 2019 / Revised: 09 December 2019 / Accepted: 23 December 2019

**ABSTRACT:** Reduced endothelial nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) in the vasculature is a feature of endothelial dysfunction. Dexamethasone causes secondary hypertension by inhibiting eNOS activity. *Piper sarmentosum* is an herb with anti-hypertensive effect. The aim of this study was to evaluate the anti-hypertensive effect of aqueous extract of *P. sarmentosum* (AEPS) in dexamethasone (Dex)-induced hypertensive rats. A total of 30 male Sprague Dawley rats were divided into five groups including control, AEPS (500 mg/kg/day, orally), Dex (20 μg/kg/day, subcutaneously), Dex (20 μg/kg/day) + AEPS (500 mg/kg/day) and Dex (20 μg/kg/day) + captopril (40 mg/kg/day, orally). Blood pressure was measured using tail-cuff method at baseline and fortnightly thereafter. The rats were sacrificed and the serum was collected to quantify the amount of NO after 28 days of treatment. Aortic samples were homogenized for measurement of eNOS mRNA expression, protein level and activity. Treatment of Dex-induced hypertensive rats with AEPS lowered systolic blood pressure (*P* < 0.001) and diastolic blood pressure (*P* < 0.01), increased eNOS mRNA expression (*P* < 0.01), eNOS protein (*P* < 0.01), eNOS activity (*P* < 0.05) and NO level (*P* < 0.05). In conclusion, AEPS reduces the blood pressure of Dex-induced hypertensive rats as it shows positive effects on eNOS and NO production.

**KEYWORDS:** Dexamethasone; endothelial nitric oxide synthase; hypertension; nitric oxide; *Piper sarmentosum*.

1. **INTRODUCTION**

Hypertension is a risk factor of cardiovascular diseases that leads to some serious complications such as stroke and ischemic heart disease [1]. Globally, 1.39 billion adults aged 20 years and above have been reported with hypertension in 2010 [2]. The prevalence of elevated systolic blood pressure (SBP) in adult population had been increasing since 1990 until 2015. It was estimated that 874 million adults had SBP of 140 mm Hg or higher in 2015 [1].

Nitric oxide (NO) is a potent vasodilator that helps to reduce total peripheral resistance and blood pressure [3]. Majority of endothelial NO is produced by endothelial nitric oxide synthase (eNOS) [4]. Reduction of NO is a cardinal feature of endothelial dysfunction which contributes to hypertension [4]. Dexamethasone (Dex) is a synthetic glucocorticoid that has been widely used to treat various diseases such as autoimmune diseases and asthma [5, 6]. Hypertension is a common side effect of chronic Dex usage [7]. Dex administration could induce hypertension via multiple mechanisms such as induction of oxidative stress, downregulation of cationic amino acid transporter-1, downregulation of eNOS and reduction of NO [8].

*Piper sarmentosum* is a medicinal herb that has been used traditionally to treat diabetes and pleurisy in Southeast Asia [9, 10]. Other studies have shown that *P. sarmentosum* has antioxidant [11, 12], anti-atherosclerosis [13] and anti-diabetic [14] activities. Toxicity studies involving 28 days oral administration of aqueous extract of *P. sarmentosum* up to 2000 mg/kg of body weight in Sprague Dawley rats reported no adverse effect [11]. In addition, *P. sarmentosum* has been shown to reduce blood pressure in spontaneously hypertensive rats by increasing NO production [12]. *P. sarmentosum* could also enhance NO production by stimulating eNOS activity in oxidative stress-induced human umbilical vein endothelial cells (HUVEC) [15].

However, there is no study that evaluates the anti-hypertensive effect of *P. sarmentosum* in Dex-induced hypertensive rat model. Therefore, this study was aimed to determine the effects of standardized aqueous extract of *P. sarmentosum* leaf (AEPS) on blood pressure, eNOS level and NO production in Dex-induced hypertensive rats.

### 2. RESULTS

#### 2.1. Effects of AEPS on blood pressure

Table 1 shows the blood pressure readings at baseline (day-0), day-14 and day-28 post treatment. At baseline, there was no significant difference among the groups in all the blood pressure parameters including systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP). Rats treated with AEPS did not show any significant changes in the blood pressure compared to the control throughout the experiment. On day 14 and 28 post-treatment, induction with Dex increased the SBP (*P < 0.001*), DBP (*P < 0.001*) and MAP (*P < 0.001*) compared to control. Treatment of Dex-induced hypertensive rats with AEPS successfully reduced the SBP (*P < 0.001*), DBP (*P < 0.01*) and MAP (*P < 0.001*) and these effects were comparable with captopril.

![Figure 1](https://doi.org/10.35333/jrp.2020.122)

**Figure 1.** Effect of AEPS on eNOS mRNA expression in dexamethasone-induced hypertensive rats (AEPS: aqueous extract of *P. Sarmentosum*; Dex: Dexamethasone; Capt: captopril; eNOS: endothelial nitric oxide synthase). Data were expressed as mean ± SEM (*n* = 6). **P < 0.01 compared with control; ##P < 0.01 and ###P < 0.001 compared with Dex group.

<table>
<thead>
<tr>
<th>Group</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
<th>MAP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>14</td>
<td>28</td>
</tr>
<tr>
<td>Control</td>
<td>112 ± 1</td>
<td>110 ± 1</td>
<td>105 ± 1</td>
</tr>
<tr>
<td>AEPS</td>
<td>115 ± 1</td>
<td>115 ± 1</td>
<td>105 ± 1</td>
</tr>
<tr>
<td>Dex</td>
<td>108 ± 1</td>
<td>136 ± 1</td>
<td>146 ± 1</td>
</tr>
<tr>
<td>Dex + AEPS</td>
<td>108 ± 1</td>
<td>111 ± 1</td>
<td>107 ± 1</td>
</tr>
<tr>
<td>Dex + Capt</td>
<td>117 ± 1</td>
<td>115 ± 1</td>
<td>105 ± 1</td>
</tr>
</tbody>
</table>

SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AEPS: aqueous extract of *Piper sarmentosum*; Dex: dexamethasone; Capt: captopril. Data are expressed as mean ± SEM; *n* = 6 in each group; **P < 0.01 and ***P < 0.001 compared to control within the same day; ****P < 0.01 compared to Dex group within the same day.

#### 2.2. Effects of AEPS on eNOS mRNA expression

AEPS treatment upregulated eNOS mRNA expression by 1.9-fold compared to control (*P < 0.01*) (Figure 1). Meanwhile, Dex downregulated eNOS mRNA expression by 0.5-fold compared to control (*P < 0.01*). Treatment of Dex-induced rats with AEPS and captopril upregulated eNOS mRNA expression by 1.4-fold (*P < 0.01*) and 1.7-fold (*P < 0.001*) respectively compared to Dex-induced group. However, there was no significant difference in eNOS mRNA expression observed between Dex + AEPS and Dex + captopril group.
2.3. Effects of AEPS on eNOS protein level

Administration of AEPS increased eNOS protein level (110.17 ± 18.98 pg/mg protein) compared to control (28.50 ± 3.64 pg/mg protein) ($P < 0.01$) (Figure 2). Induction with Dex caused a reduction in eNOS protein level (10.17 ± 1.54 pg/mg protein; $P < 0.01$). Moreover, treatment of Dex-induced hypertensive rats with AEPS increased eNOS protein level (40.17 ± 9.51 pg/mg protein; $P < 0.01$). Besides, Dex + captopril group also showed an increase in eNOS protein level (46.67 ± 7.37 pg/mg protein; $P < 0.01$). There was no significant difference shown in eNOS protein level between Dex + AEPS and Dex + captopril group.

Figure 2. Effect of AEPS on eNOS protein level in dexamethasone-induced hypertensive rats. Data were expressed as mean ± SEM ($n = 6$). *$P < 0.01$ compared with control; #*$P < 0.01$ compared with Dex group. AEPS: aqueous extract of P. sarmentosum; Dex: dexamethasone; Capt: captopril; eNOS: endothelial nitric oxide synthase.

2.4. Effects of AEPS on eNOS activity

Treatment with AEPS increased eNOS activity (2.1 ± 0.231 μM nitrite/min/mg protein) compared to control (1.4 ± 0.103 nitrite/min/mg protein) ($P < 0.05$) (Figure 3). Dex inhibited eNOS activity (1.1 ± 0.073 μM nitrite/min/mg protein) compared with control ($P < 0.05$). AEPS was able to stimulate eNOS activity in Dex-induced hypertensive rats (1.4 ± 0.109 μM nitrite/min/mg protein; $P < 0.05$). Captopril also increased eNOS activity in Dex-induced hypertensive rats (1.4 ± 0.201 μM nitrite/min/mg protein; $P < 0.05$). There was no significant difference in eNOS activity between Dex + AEPS and Dex + captopril group.

Figure 3. Effect of AEPS on eNOS activity in dexamethasone-induced hypertensive rats. Data are expressed as mean ± SEM ($n = 6$). *$P < 0.05$ compared with control; #*$P < 0.05$ compared with Dex group. AEPS: aqueous extract of P. sarmentosum; Dex: dexamethasone; Capt: captopril; eNOS: endothelial nitric oxide synthase.

2.5. Effects of AEPS on NO Level

NO level in rats treated with AEPS (78.6 ± 8.01 μM) was increased compared with control (52.8 ± 7.03 μM) ($P < 0.05$) (Figure 4). Serum NO level was decreased in rats induced with Dex (31.0 ± 5.18 μM) compared to control ($P < 0.05$). AEPS treatment in Dex-induced hypertensive rats resulted in increased NO (56.8 ± 6.22 μM, $P < 0.05$). Captopril also increased serum NO level in Dex-induced hypertensive rats (56.1 ± 6.14 μM, $P <
0.05). However, there was no significant difference in NO level between Dex + AEPS and Dex + captopril group.

![Image](https://doi.org/10.35333/jrp.2020.122)

**Figure 4.** Effect of AEPS on nitric oxide level in dexamethasone-induced hypertensive rats. Data were expressed as mean ± SEM (n = 6). *P < 0.05 compared with the control; #P < 0.05 compared with the Dex group. AEPS: aqueous extract of *P. sarmentosum*; Dex: dexamethasone; Capt: captopril; eNOS: endothelial nitric oxide synthase.

3. DISCUSSION

Lack of endothelial NO is a feature of endothelial dysfunction that is involved in the pathogenesis of hypertension [4]. Fortnightly blood pressure measurements following induction with 20 μg/kg/day dexamethasone indicated that the rats were in hypertensive state. Previous study has found that subcutaneous injection of dexamethasone at similar dose has increased SBP and DBP on day 5 post-induction [16]. The results also showed that Dex-induced hypertensive rats had lower expression of eNOS mRNA, protein and activity as well as lower serum NO level. Current findings were in concurrent with previous studies whereby Dex-induced hypertensive rats had lower expression of eNOS mRNA, protein and activity [17]. Downregulation of eNOS mRNA expression had caused less eNOS protein to be synthesized and subsequently led to decreased eNOS activity and NO production. Dex reduces NO production through several mechanisms including reduction of eNOS substrate L-arginine and reduction in the synthesis of eNOS cofactor such as tetrahydrobiopterin (BH₄) by GTP cyclohydrolase [18]. Lack of BH₄ leads to eNOS uncoupling and results in increased superoxide production and reduced NO bioavailability [18].

AEPS was effective in reducing the blood pressure of Dex-induced hypertensive rats. Treatment of Dex-induced hypertensive rats with AEPS enhanced eNOS mRNA level, protein level and activity as well as NO level. Upregulation of eNOS mRNA expression had caused more eNOS protein to be synthesized and led to increased eNOS activity and NO production. In cultured HUVEC, AEPS stimulated endothelial cells to produce NO by increasing eNOS mRNA expression, protein level and activity [15]. Besides, AEPS has antioxidant activity which could contribute to the increased bioavailability of NO [12]. Moreover, antioxidant protects NO from oxidative degradation by reactive oxygen species and therefore preserves NO bioavailability [18]. In spontaneously hypertensive rats, AEPS could lower the blood pressure by reducing oxidative stress and increasing NO level [12]. Therefore, the blood pressure lowering effect of AEPS in this study might be arisen from its antioxidant effect, which needs to be clarified with future studies.

Standardized AEPS contains the flavonoids rutin and vitexin [19]. Previous study had shown that rutin increased NO production by inducing eNOS mRNA expression, protein synthesis and activity in HUVEC [19]. Oral administration of rutin decreased SBP and DBP of sodium chloride-induced hypertensive rats [20]. In addition, vitexin lowered the blood pressure and total cholesterol of NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive mice. Thus, the anti-hypertensive effect of AEPS may be due to the actions of the aforementioned flavonoids.

In this study, the anti-hypertensive effect of AEPS was compared with captopril, an angiotensin converting enzyme (ACE) inhibitor. Treatment of Dex-induced hypertensive rats with captopril had reduced the blood pressure and increased the eNOS mRNA expression, protein level and activity as well as NO level. Captopril had also been reported to give a positive impact on the production of NO in previous studies. Treatment with captopril decreased the blood pressure by increasing the expression of eNOS in aortic tissues and restoring the plasma NO level in L-NAME-induced hypertensive rats [21]. There was no significant difference observed between the effects of AEPS and captopril on the blood pressure, eNOS level and serum...
NO in Dex-induced hypertensive rats. This shows that AEPS has similar anti-hypertensive effect with captopril in Dex-induced hypertensive rats.

This experiment was an in vivo animal study that investigated some fundamental anti-hypertensive effects of AEPS. The data suggested that AEPS could reduce Dex-induced hypertension by increasing NO. However, further pharmacological evaluations are required to identify and isolate the anti-hypertensive compounds in AEPS as well as elucidating their mechanisms of action. In addition, clinical trials with large sample size and excellent methodological quality will also be needed to provide a confirmed conclusion of the effectiveness and safety of AEPS as a treatment for hypertension in humans.

4. CONCLUSION

The present study shows that AEPS reduces blood pressure in Dex-induced hypertensive rats by stimulating eNOS activity and NO production. Therefore, AEPS has the potential to be developed as an anti-hypertensive agent in the future. Further studies are needed to corroborate these findings.

5. MATERIALS AND METHODS

5.1. Preparation of standardized aqueous extract of *P. sarmentosum* (AEPS)

Leaves of *P. sarmentosum* were purchased from Herbagus Sdn. Bhd, Penang, Malaysia and was authenticated by a plant taxonomist from Faculty of Science and Technology, Universiti Kebangsaan Malaysia (voucher specimen number: UKMB40240). AEPS was prepared and standardized to contain 0.52% (w/w) vitexin and 0.76% (w/w) rutin as described previously [22]. Fresh leaves of *P. sarmentosum* were cleaned with tap water and oven-dried at 40 °C for four days. Dried *P. sarmentosum* leaves were grinded and mixed with distilled water (1:10, w/v) in a high-speed mixer. Then, the mixture was boiled at 80 °C for three hours. AEPS was filtered and concentrated repeatedly, followed by freeze-drying. The powdered form of AEPS was then stored at 4 °C. High performance liquid chromatography (HPLC) analysis was carried out using HPLC system (Waters Delta 600 with 600 Controller) with photodiode array detector (Waters 996) to quantify the amount of rutin and vitexin in the extract.

Figure 5(a) shows the chromatogram of AEPS. The retention times (Rt) of the major peaks in the chromatogram of AEPS were compared with the Rt of rutin and vitexin. Peak E in the chromatogram (Rt = 15.387 min) corresponded to vitexin (Rt = 15.382 min) (Figure 5(b)) while peak F (Rt = 17.449 min) corresponded to rutin (Rt = 17.450 min) (Figure 5(d)). The sample was spiked with vitexin and rutin and the results confirmed the presence of vitexin (Figure 5(c)) and rutin (Figure 5(e)). Quantitative analysis of rutin and vitexin was carried out with reference to the standard curves of rutin (y = 13487x - 181561, r² = 0.995) and vitexin (y = 12313x - 18598, r² = 0.998). The concentration of vitexin in AEPS was 51.93 ± 0.55 ppm (0.5193%) while the concentration of rutin was 75.70 ± 0.50 ppm (0.7570%).

5.2. Animals and experimental design

The study was approved by the Animal Ethics Committee, Universiti Kebangsaan Malaysia (Approval Number: FP/FISIO/2015/ZAITON/11-FEB.-639-FEB.-2015-SEPT.-2016) and was carried out in adherence to the Guidelines of Care and Use of Laboratory Animals, The National Academic Press. A total of 30 male Sprague Dawley (SD) rats, aged between 8 to 12 weeks old, were obtained from Animal Unit, Universiti Kebangsaan Malaysia, Kuala Lumpur. Rats were housed in plastic cages at constant laboratory temperature (22 ± 3 °C) and maintained under 12:12 hours light: dark cycle throughout the experiment. Rats were fed with pelleted and given water *ad libitum*. The animals were acclimatized for one week under the standard conditions before performing any experimental procedure.

The rats were then randomly allocated into five groups in which each group consists of six rats (n=6). Rats in group 1 (control) received normal saline orally, whereas rats in group 2 received AEPS (500 mg/kg/day) orally. Dex (20 μg/kg/day) (Cayman Chemical, USA) was injected subcutaneously (s.c) to induce hypertension in groups 3, 4 and 5. Group 4 received concomitant Dex and AEPS (500 mg/kg/day) while group 5 received concomitant Dex and captopril (40 mg/kg/day given orally) (Cayman Chemical, USA). All the treatments were given for a total of 28 days.

The dose of dexamethasone (20 μg/kg/day) was chosen as it had been shown to induce hypertension in rats [16]. The dose and treatment duration for AEPS (500 mg/kg/day for 28 days) were adopted from previous studies which showed that AEPS at similar dose and treatment duration successfully reduced BP and increased NO in spontaneously hypertensive and L-NAME-induced hypertensive rats [12, 23].

https://doi.org/10.35333/jrp.2020.122
J Res Pharm 2020; 24(1): 150-158
Rats were sacrificed on day 29 using zoletil and xylazine (Virbac, France). The blood samples were collected using cardiac puncture. Thoracic aortae were dissected and cleaned off the surrounding connective tissues prior to homogenization for further tests.

Figure 5. HPLC chromatograms of (a) aqueous extract of *Piper sarmentosum* (AEPS) (b) vitexin (c) AEPS + vitexin (d) rutin and (e) AEPS + rutin.
5.3. Measurement of blood pressure

Systolic and diastolic blood pressure in conscious, restrained rats were measured at baseline (day 0), day 14 and day 28 using CODA™-non-invasive tail cuff system (Kent Scientific Corporation, USA). The interval of blood pressure measurements every fortnight was adopted from previous studies [12, 23]. The rats were placed on a heated chambers at 37 °C during the measurement. At least five readings were recorded for each rat. The highest and the lowest readings were manually discarded and the average of the remaining three readings were taken as the blood pressure value [23].

5.4. Determination of eNOS mRNA expression

Total RNA was extracted from thoracic aorta samples using TRI reagent (MRC, USA) as described previously [24]. cDNA synthesis was carried out using SuperScript® Green Master Mix (ThermoFisher Scientific, USA). eNOS mRNA expression in the samples was measured using quantitative real time reverse transcriptase polymerase chain reaction (qPCR). Table 2 shows the primer sequence used in the reaction. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the control gene. The reaction was conducted using the thermocycling conditions as follows: initial denaturation at 95 °C for 3 minutes, followed by 40 cycles of amplification at 95 °C for 10 s, annealing at 58 °C for 30 seconds and extension at 72 °C for a minute. Each sample was run in duplicates. The specificity of the PCR reactions was verified by melting curve analysis and 0.8% agarose gel electrophoresis. mRNA expression of eNOS was calculated based on the threshold cycle (CT) value through the formula 2−∆∆CT, whereby ∆∆CT = CT GAPDH - CT eNOS [24].

<table>
<thead>
<tr>
<th>Gene</th>
<th>NCBI number</th>
<th>Primer Sequence (5’ to 3’)</th>
<th>Product Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>NM_017008.4</td>
<td>Forward GTACCAGGGCTGCTTCTTC</td>
<td>177</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reverse GATGGTGATTGGTTCCCGT</td>
<td></td>
</tr>
<tr>
<td>eNOS</td>
<td>NM_021838.2</td>
<td>Forward AGCGGCTGTACATGAGTTTC</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reverse CCGGGTGTCATAGCCCATGC</td>
<td></td>
</tr>
</tbody>
</table>

5.5. Determination of eNOS protein level

eNOS protein level in the thoracic aorta tissues was determined using enzyme-linked immunosorbent assay (ELISA) kit for rat’s nitric oxide synthase 3 (USCN Life Science Inc, USA) according to the manufacturer’s protocol. Aortic tissues were homogenized in 10 ml of phosphate buffered saline (PBS), centrifuged at 5000 g for 5 minutes and the supernatant was collected. Samples were incubated in a 96-well plate containing biotin-conjugated antibody specific to eNOS. After washing, the horseradish peroxidase-conjugated avidin was added followed by tetramethylbenzidine substrate solution. Optical densities (OD) of the wells were quantified at 450 nm using spectrophotometer. Total protein concentration in the samples was determined using Bradford method [25]. eNOS protein level was expressed as pg/mg of total protein.

5.6. Determination of eNOS activity

EnzyChrome™ Nitric Oxide Synthase Assay kit (Bioassay System, USA) was used to determine eNOS activity. The principle of this assay was based on the measurement of nitrite produced by eNOS in the sample in a timed reaction. Aortic tissues were homogenized, centrifuged and the supernatant was collected as samples. The samples were then incubated for 20 minutes at 37 °C in a buffer containing eNOS cofactor (tetrahydrobiopterin) and substrate (L-arginine). Each sample was tested in triplicates. The reaction mixture was centrifuged at 14000 g for 10 minutes and the supernatant was mixed with Griess reagents (sulfanilamide and N-(1-Naphthyl)ethylenediamine dihydrochloride). Total nitrite was measured at 540 nm. Protein concentration in the samples was determined using Bradford method [25]. eNOS activity was expressed as mM nitrite/min/mg protein.

5.7. Determination of NO level

 Serum NO concentration was measured using QuantiChrom™ Nitric Oxide Assay kit (Bioassay System, USA) following the manufacturer’s protocol. Samples were mixed with Griess reagents (sulfanilamide and N-(1-Naphthyl) ethylenediamine dihydrochloride). Subsequently, vanadium solution was added to the wells to allow reduction of nitrate to nitrite and the absorbance was measured at 540 nm.
5.8. Statistical analysis

Statistical analyses were performed using SPSS version 22.0 software. Data were tested for normality using Shapiro-Wilk test and analysed using two-way analysis of variance (ANOVA) and post hoc Tukey test. All the data were expressed as mean ± S.E.M. Value of $P < 0.05$ was considered to be statistically significant.

Acknowledgements: This research was funded by Universiti Kebangsaan Malaysia Medical Centre Fundamental Grant (FF-2017-040). We would like to thank Mr. Roger Davies for proof reading this paper.


Conflict of interest statement: The authors declared no conflict of interest.

Ethics committee approval: The study was approved by the Animal Ethics Committee, Universiti Kebangsaan Malaysia (Approval Number: FP/FISIO/2015/ZAITON/11-FEB./639-FEB.-2015-SEPT. -2016)

REFERENCES


This is an open access article which is publicly available on our journal's website under Institutional Repository at http://dspace.marmara.edu.tr.